US7605155B2
(en)
*
|
2002-09-04 |
2009-10-20 |
Schering Corporation |
Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
|
US7563798B2
(en)
*
|
2002-09-04 |
2009-07-21 |
Schering Corporation |
Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
|
US7196078B2
(en)
*
|
2002-09-04 |
2007-03-27 |
Schering Corpoartion |
Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US7601724B2
(en)
*
|
2002-09-04 |
2009-10-13 |
Schering Corporation |
Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
|
US7119200B2
(en)
*
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
JP2006501260A
(ja)
*
|
2002-09-04 |
2006-01-12 |
シェーリング コーポレイション |
サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
|
WO2004076458A1
(en)
*
|
2003-02-28 |
2004-09-10 |
Teijin Pharma Limited |
Pyrazolo[1,5-a]pyrimidine derivatives
|
GB0305559D0
(en)
*
|
2003-03-11 |
2003-04-16 |
Teijin Ltd |
Compounds
|
US20070179161A1
(en)
*
|
2003-03-31 |
2007-08-02 |
Vernalis (Cambridge) Limited. |
Pyrazolopyrimidine compounds and their use in medicine
|
EP1473293B1
(de)
*
|
2003-04-30 |
2008-03-19 |
MERCK PATENT GmbH |
Chromenonderivate
|
AU2004272437A1
(en)
*
|
2003-09-09 |
2005-03-24 |
Ono Pharmaceutical Co., Ltd. |
CRF antagonists and heterobicyclic compounds
|
JP2007533749A
(ja)
*
|
2004-04-20 |
2007-11-22 |
アムゲン インコーポレイティッド |
アリールスルホンアミドおよびそれに関連する使用方法
|
GB0412553D0
(en)
|
2004-06-04 |
2004-07-07 |
Univ Aberdeen |
Therapeutic agents for the treatment of bone conditions
|
EP2862859B1
(de)
|
2004-06-17 |
2018-07-25 |
Cytokinetics, Inc. |
Verbindungen, zusammensetzungen und verfahren
|
RU2007109155A
(ru)
*
|
2004-08-13 |
2008-09-20 |
Тейдзин Фарма Лимитед (Jp) |
Пиразоло[1, 5-]пиримидиновые производные
|
US7667036B2
(en)
|
2004-08-13 |
2010-02-23 |
Teijin Pharma Limited |
Pyrazolo[1,5-a]pyrimidine derivatives
|
US7745446B2
(en)
|
2004-09-06 |
2010-06-29 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolo[1,5-c]pyrimidines
|
GB0515026D0
(en)
*
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
WO2007017678A1
(en)
*
|
2005-08-09 |
2007-02-15 |
Eirx Therapeutics Limited |
Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
|
EP2275095A3
(de)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenese durch modulation des Muscarinrezeptors
|
EP2258358A3
(de)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
ATE478852T1
(de)
|
2005-09-09 |
2010-09-15 |
Schering Corp |
Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
|
AR056206A1
(es)
*
|
2005-10-06 |
2007-09-26 |
Schering Corp |
Pirazolpirimidinas como inhibidores de protein quinasas
|
NZ567151A
(en)
*
|
2005-10-06 |
2012-03-30 |
Schering Corp |
Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
AR058347A1
(es)
|
2005-12-15 |
2008-01-30 |
Cytokinetics Inc |
Entidades quimias composiciones y metodos
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
EP2027127A1
(de)
*
|
2006-05-22 |
2009-02-25 |
Shering Corporation |
Pyrazolo [1,5-a] pyrimidine als cdk-hemmer
|
JP5247699B2
(ja)
*
|
2006-08-18 |
2013-07-24 |
メルク・シャープ・アンド・ドーム・コーポレーション |
キラルピペリジンアルコールの分割プロセスおよびピペリジンアルコールを用いるピラゾロ−[1,5]−ピリミジン誘導体の合成プロセス
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2076497B1
(de)
*
|
2006-10-19 |
2012-02-22 |
F. Hoffmann-La Roche AG |
Aminomethyl-4-imidazole
|
DE102007012645A1
(de)
*
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
GB0705400D0
(en)
|
2007-03-21 |
2007-05-02 |
Univ Aberdeen |
Therapeutic compounds andm their use
|
DE102007032349A1
(de)
*
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
KR20100133385A
(ko)
*
|
2008-02-26 |
2010-12-21 |
노파르티스 아게 |
Cxcr2의 억제제로서의 헤테로시클릭 화합물
|
TW200944526A
(en)
*
|
2008-04-22 |
2009-11-01 |
Vitae Pharmaceuticals Inc |
Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
|
KR101353857B1
(ko)
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Cdk 억제제로서 피롤로피리미딘 화합물
|
GB0817207D0
(en)
|
2008-09-19 |
2008-10-29 |
Pimco 2664 Ltd |
therapeutic apsac compounds and their use
|
GB0817208D0
(en)
|
2008-09-19 |
2008-10-29 |
Pimco 2664 Ltd |
Therapeutic apsap compounds and their use
|
RS53350B
(en)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
|
SG10201914059WA
(en)
|
2008-10-22 |
2020-03-30 |
Array Biopharma Inc |
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
|
JP5683489B2
(ja)
*
|
2009-01-12 |
2015-03-11 |
アレイ バイオファーマ、インコーポレイテッド |
ピペリジン含有化合物およびその用途
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2010118207A1
(en)
|
2009-04-09 |
2010-10-14 |
Schering Corporation |
Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
EP2475652A1
(de)
*
|
2009-09-11 |
2012-07-18 |
Cylene Pharmaceuticals, Inc. |
Pharmazeutisch nützliche heterocyclensubstituierte lactame
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
US9227971B2
(en)
|
2010-01-19 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
WO2011094953A1
(en)
*
|
2010-02-08 |
2011-08-11 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment and prevention of influenza
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
SG10201506591TA
(en)
|
2010-05-20 |
2015-09-29 |
Array Biopharma Inc |
Macrocyclic compounds as trk kinase inhibitors
|
PT2713722T
(pt)
|
2011-05-31 |
2017-06-27 |
Receptos Llc |
Novos estabilizadores e moduladores do receptor glp-1
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
WO2013144532A1
(en)
*
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CA2889919C
(en)
|
2012-11-16 |
2021-08-17 |
University Health Network |
Pyrazolopyrimidine compounds
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
AU2013370417A1
(en)
*
|
2012-12-28 |
2015-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物
|
EP2970288A1
(de)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinaseinhibitoren nützliche verbindungen
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
US9260427B2
(en)
|
2013-06-11 |
2016-02-16 |
Receptos, Inc. |
GLP-1 receptor modulators
|
GB201311361D0
(en)
|
2013-06-26 |
2013-08-14 |
Pimco 2664 Ltd |
Compounds and their therapeutic use
|
JP6491202B2
(ja)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
RU2720408C2
(ru)
|
2013-12-06 |
2020-04-29 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения ингибиторов atr киназы (варианты)
|
GB201403093D0
(en)
|
2014-02-21 |
2014-04-09 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
PT3126352T
(pt)
|
2014-04-04 |
2018-12-27 |
Syros Pharmaceuticals Inc |
Inibidores da quinase dependente de ciclina 7 (cdk7)
|
WO2015154022A1
(en)
*
|
2014-04-05 |
2015-10-08 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
RU2719583C2
(ru)
|
2014-06-05 |
2020-04-21 |
Вертекс Фармасьютикалз Инкорпорейтед |
Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
|
CA2950780C
(en)
|
2014-06-17 |
2023-05-16 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
CN107428760B
(zh)
|
2014-11-16 |
2021-04-27 |
阵列生物制药公司 |
(s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
|
US9795613B2
(en)
|
2014-12-10 |
2017-10-24 |
Celgene International Ii Sàrl |
GLP-1 receptor modulators
|
HRP20211877T1
(hr)
|
2014-12-17 |
2022-03-04 |
Pimco 2664 Limited |
Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
EP3273966B1
(de)
*
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Hemmer von cyclinabhängigen kinasen
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
GB201517263D0
(en)
*
|
2015-09-30 |
2015-11-11 |
Ucb Biopharma Sprl And Katholieke Universiteit Leuven |
Therapeutic agents
|
JP7187308B2
(ja)
|
2015-09-30 |
2022-12-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法
|
CA3003153A1
(en)
|
2015-10-26 |
2017-05-04 |
Loxo Oncology, Inc. |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
UA125026C2
(uk)
|
2016-04-04 |
2021-12-29 |
Локсо Онколоджі, Інк. |
РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
UA127826C2
(uk)
|
2016-05-18 |
2024-01-17 |
Локсо Онколоджі, Інк. |
СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
|
WO2018033918A1
(en)
|
2016-08-18 |
2018-02-22 |
Vidac Pharma Ltd. |
Piperazine derivatives, pharmaceutical compositions and methods of use thereof
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
WO2018082444A1
(zh)
*
|
2016-11-02 |
2018-05-11 |
叶宝欢 |
吡唑并嘧啶化合物作为pi3k抑制剂及其应用
|
CN108017641B
(zh)
*
|
2016-11-02 |
2021-01-05 |
深圳铂立健医药有限公司 |
吡唑并嘧啶化合物作为pi3k抑制剂及其应用
|
MA47591A
(fr)
*
|
2017-02-27 |
2020-01-01 |
Janssen Pharmaceutica Nv |
Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
PL233595B1
(pl)
*
|
2017-05-12 |
2019-11-29 |
Celon Pharma Spolka Akcyjna |
Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
|
MX2020001103A
(es)
|
2017-07-28 |
2020-08-17 |
Nimbus Lakshmi Inc |
Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
|
GB201715194D0
(en)
|
2017-09-20 |
2017-11-01 |
Carrick Therapeutics Ltd |
Compounds and their therapeutic use
|
KR102622644B1
(ko)
|
2017-10-04 |
2024-01-10 |
바이엘 악티엔게젤샤프트 |
해충 방제제로서의 헤테로시클릭 화합물의 유도체
|
TWI795510B
(zh)
|
2018-01-17 |
2023-03-11 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
PI4KIIIβ抑制劑
|
ES2925914T3
(es)
|
2018-03-12 |
2022-10-20 |
Bayer Ag |
Derivados heterocíclicos condensados como plaguicidas
|
AU2019254499A1
(en)
|
2018-04-20 |
2020-12-03 |
Bayer Aktiengesellschaft |
Heterocyclene derivatives as pest control agents
|
JP7179161B2
(ja)
|
2018-09-10 |
2022-11-28 |
イーライ リリー アンド カンパニー |
乾癬および全身性エリテマトーデスの処置に有用なピラゾロ[1,5-a]ピリミジン-3-カルボキサミド誘導体
|
US11155560B2
(en)
*
|
2018-10-30 |
2021-10-26 |
Kronos Bio, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
|
TWI810520B
(zh)
|
2020-02-12 |
2023-08-01 |
美商美國禮來大藥廠 |
7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
|
WO2022187518A1
(en)
*
|
2021-03-03 |
2022-09-09 |
Ikena Oncology, Inc. |
Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions
|
GB202108572D0
(en)
*
|
2021-06-16 |
2021-07-28 |
Carrick Therapeutics Ltd |
Therapeutic compounds and their use
|
WO2024054602A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|